Scarica l'app Stockscreener
0.8755
5.49%
-0.0509
Dopo l'orario di chiusura:
.89
0.0145
+1.66%
Precedente Chiudi:
$0.9264
Aprire:
$0.8682
Volume 24 ore:
388.30K
Relative Volume:
0.58
Capitalizzazione di mercato:
$54.61M
Reddito:
-
Utile/perdita netta:
$-71.17M
Rapporto P/E:
-0.6299
EPS:
-1.39
Flusso di cassa netto:
$-70.97M
1 W Prestazione:
-11.98%
1M Prestazione:
-19.68%
6M Prestazione:
-82.70%
1 anno Prestazione:
-87.79%
Intervallo 1D:
$0.8234
$0.899
Intervallo di 1 settimana:
$0.8234
$1.03
Portata 52W:
$0.8234
$7.31
Inozyme Pharma Inc Stock (INZY) Company Profile
Nome
Inozyme Pharma Inc
Settore
Industria
Telefono
857-330-4340
Indirizzo
321 SUMMER STREET, BOSTON
Confronta INZY con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
INZY
Inozyme Pharma Inc
|
0.8755 | 54.61M | 0 | -71.17M | -70.97M | -1.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.01 | 125.55B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
610.64 | 67.78B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
590.06 | 36.24B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
262.16 | 33.99B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
264.32 | 28.77B | 3.81B | -644.79M | -669.77M | -6.24 |
Inozyme Pharma Inc Stock (INZY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-12 | Iniziato | Raymond James | Outperform |
| 2024-09-12 | Iniziato | Stifel | Buy |
| 2024-08-13 | Ripresa | Jefferies | Buy |
| 2024-05-30 | Iniziato | Wells Fargo | Overweight |
| 2023-03-23 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-05-26 | Iniziato | Jefferies | Hold |
| 2022-02-07 | Iniziato | H.C. Wainwright | Buy |
| 2021-11-29 | Iniziato | Needham | Buy |
| 2020-08-18 | Iniziato | BofA Securities | Buy |
| 2020-08-18 | Iniziato | Cowen | Outperform |
| 2020-08-18 | Iniziato | Piper Sandler | Overweight |
| 2020-08-18 | Iniziato | Wedbush | Outperform |
Mostra tutto
Inozyme Pharma Inc Borsa (INZY) Ultime notizie
Rare Disease Innovator Inozyme Pharma Reveals Latest Progress at Elite Healthcare Conference - Stock Titan
Inozyme Pharma to Participate in the 24th Annual Needham Virtual Healthcare Conference - Bluefield Daily Telegraph
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of “Buy” by Brokerages - Defense World
Inozyme Pharma stock hits 52-week low at $0.98 amid sharp decline By Investing.com - Investing.com South Africa
Inozyme Pharma stock hits 52-week low at $0.98 amid sharp decline - Investing.com Australia
FY2027 EPS Estimates for Inozyme Pharma Raised by Analyst - Defense World
Raymond James Issues Pessimistic Forecast for Inozyme Pharma (NASDAQ:INZY) Stock Price - Defense World
Q1 Earnings Estimate for Inozyme Pharma Issued By Wedbush - Defense World
Q1 EPS Estimates for Inozyme Pharma Reduced by HC Wainwright - Defense World
Piper Sandler Has Lowered Expectations for Inozyme Pharma (NASDAQ:INZY) Stock Price - Defense World
Inozyme Pharma (NASDAQ:INZY) Price Target Lowered to $15.00 at Needham & Company LLC - Defense World
Inozyme Pharma’s (INZY) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Piper Sandler cuts Inozyme Pharma stock target to $23 By Investing.com - Investing.com Australia
Inozyme Pharma stock hits 52-week low at $1.03 amid sharp decline - Investing.com
Piper Sandler cuts Inozyme Pharma stock target to $23 - Investing.com
H.C. Wainwright maintains Buy on Inozyme stock with $16 target By Investing.com - Investing.com Australia
H.C. Wainwright maintains Buy on Inozyme stock with $16 target - Investing.com
Wedbush Reaffirms Outperform Rating for Inozyme Pharma (NASDAQ:INZY) - The AM Reporter
Inozyme Pharma Focuses on ENPP1 Deficiency Program - TipRanks
Inozyme Pharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Wedbush Cuts Inozyme Pharma Price Target to $7 From $12, Maintains Outperform Rating - Marketscreener.com
Inozyme reports prioritization of ENPP1 Deficiency program, workforce reduction - TipRanks
Inozyme Pharma Reports 2024 Financial Results and Strategic Prioritization of ENPP1 Deficiency Program - Nasdaq
Inozyme Pharma, Inc. SEC 10-K Report - TradingView
Form 10-K Inozyme Pharma, Inc. For: Dec 31 - StreetInsider
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization ... - Bluefield Daily Telegraph
Inozyme Pharma Reports Full Year 2024 Financial Results and Announces Strategic Prioritization of ENPP1 Deficiency Pivotal Program and Recent Business Highlights - The Manila Times
Inozyme Pharma Reports Full Year 2024 Financial Results and - GlobeNewswire
Inozyme Pharma (INZY) Projected to Post Earnings on Tuesday - Defense World
Inozyme Pharma Inc expected to post a loss of 41 cents a shareEarnings Preview - TradingView
Inozyme Pharma, Inc. (NASDAQ:INZY) Receives $18.33 Consensus PT from Analysts - Armenian Reporter
INZY stock touches 52-week low at $1.14 amid market challenges - Investing.com
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Rating of "Buy" by Brokerages - MarketBeat
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Average Rating of “Buy” by Brokerages - Defense World
Inozyme Pharma stock hits 52-week low at $1.23 amid challenges - Investing.com Canada
Inozyme Pharma to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewswire
Can Inozyme's Rare Disease Pipeline Transform Bone Health Treatment? CEO Presents Key Data - StockTitan
Inozyme Pharma to Present Recently Announced Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency at CHOP Cardiology 2025 - The Manila Times
Inozyme Pharma to Present Recently Announced Interim Data - GlobeNewswire
Can This Rare Disease Treatment Transform Young Lives? New ENPP1 Therapy Data Emerges - StockTitan
Inozyme Pharma stock hits 52-week low at $1.32 amid market challenges - MSN
abrdn plc Makes New $472,000 Investment in Inozyme Pharma, Inc. (NASDAQ:INZY) - Defense World
Inozyme Pharma Inc (NASDAQ: INZY) Stock Falling -48.58% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel
Inozyme Pharma, Inc. (NASDAQ:INZY) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
INZY Stock: A Comprehensive Analysis and Forecast - The InvestChronicle
Was anything positive for Inozyme Pharma Inc (INZY) stock last session? - US Post News
Inozyme Pharma Inc Azioni (INZY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.23%
1.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):